| |
-K+
-K+, Urine
-K, Body Fluid
-Karyotype
-KCN
-Keppra
-Ketone Bodies
-Ketones, Semiquantitative
-Kidney Biopsy
-Kidney Stone Analysis
-Kidney Stone Diagnostic Risk Profile (KSP)
-Kidney Stone Risk Profile
-Kleihauer-Betke Test (KLB)
-KOH/Calcofluor Prep (KOH)
-KRAS Mutation (KRAS)
|
|
|
|
Print |
| K+ |
| |
| See Potassium, Serum |
Print |
| K+, Urine |
| |
| See Potassium, Urine |
Print |
| K, Body Fluid |
| |
| See Potassium, Body Fluid |
Print |
| Karyotype |
| |
| See Chromosome Analysis, Blood |
Print |
| KCN |
| |
| See Thiocyanate |
Print |
| Keppra |
| |
| See Levetiracetam |
Print |
| Ketone Bodies |
| |
| See Acetone, Semiquantitative |
Print |
| Ketones, Semiquantitative |
| |
| See Acetone, Semiquantitative |
Print |
| Kidney Biopsy |
| |
| See Histopathology, Renal Biopsy |
Print |
| Kidney Stone Analysis |
| |
| See Stone Analysis |
Print |
| Kidney Stone Diagnostic Risk Profile |
| |
| Includes: |
• Volume Measurement • Collection Period • Calcium, Urine • Chloride, Urine • Citrate Excretion, Urine • Creatinine, Urine • Oxalate, Urine • pH, Urine • Phosphorus, Urine • Potassium, Urine • Sodium, Urine • Uric Acid, Urine |
| |
| CPT: |
81050. 82340, 82436, 82507, 82570, 83945, 81002, 84105, 84133, 84300, 84560 |
| |
| Alternate Name: |
Kidney Stone Risk Profile |
| |
| Methodology: |
See individual test listings. |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Entire 24 hour urine collection . |
| |
| Container: |
24-Hour plastic urine container, no preservative |
| |
| Collection: |
24-Hour urine collection: See special instructions for “24-Hour Urine Collection”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
| Patient should maintain a normal diet prior to testing. |
| |
| Reference Range: |
| See Individual test listings |
| |
Print |
| Kidney Stone Risk Profile |
| |
| See Kidney Stone Diagnostic Risk Profile |
Print |
| Kleihauer-Betke Test |
| |
| CPT: |
85460 |
| |
| Alternate Name: |
Acid Elution for Fetal Hemoglobin; Fetal Hemoglobin Stain; Fetal-Maternal Hemorrhage Test |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.5 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Reference Range: |
| 0 mL of fetal-maternal hemorrhage |
| |
| Clinical Utility: |
| Used to determine possible fetal-maternal hemorrhage. |
| |
Print |
| KOH/Calcofluor Prep |
| |
| Includes: |
Microscopic examination for fungal elements. |
| |
| CPT: |
87220 |
| |
| Alternate Name: |
Fungus Smear; Potassium Hydroxide Preparation |
| |
| Methodology: |
KOH Prep |
| |
| Testing Schedule: |
Routine, Monday-Friday 0800-1430 |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Hair, skin, nails in sterile dry container |
| |
| Collection: |
The specimen may be divided for fungus culture and KOH preparation; mycobacteria culture and smear; and routine bacterial culture and Gram stain, only if the specimen is of adequate volume for all tests requested. |
| |
| Special Instructions and/or Comments: |
| Requisition Form must include site of specimen collection. |
| |
| Reference Range: |
| No fungal elements identified. |
| |
| Clinical Utility: |
Fungal direct exam detects the presence of fungi directly from a clinical specimen. |
| |
Print |
| KRAS Mutation |
| |
| Includes: |
Detection of KRAS mutation in colon 12 and 13 of exon 2 |
| |
| CPT: |
83891, 83898, 83896 x 2, 83907, 83912 |
| |
| Methodology: |
Real-time PCR |
| |
| Testing Schedule: |
Routine, 1 day per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Four freshly cut sections of Formalin-fixed Paraffin Embedded tumor tissue |
| |
| Container: |
Transfer freshly cut sections to a 2.0 mL tube.Add 1 mL xylene |
| |
| Special Instructions and/or Comments: |
| Fix tissue samples in 4-10% formalin as quickly as possible after surgical removal. Use a fixation time of 14-24 hours. Thoroughly dehydrate samples prior to embedding |
| |
| Reference Range: |
| KRAS Mutation Not Detected.. |
| |
| Clinical Utility: |
| The presence of KRAS mutation in Colorectal cancer tumors correlates with poor prognosis and is associated with lack of response to EGFR inhibitors. Studies have demonstrated that patients with KRAS mutations would not benefit from anti-EGFR therapy and therefore KRAS status should be determined prior to treatment. |
| |
|